TCGA-A8-A08B-01A-11R-A00Z-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 39
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- E2F_TARGETS+0.450
- MYC_TARGETS_V1+0.450
- MYC_TARGETS_V2+0.430
- G2M_CHECKPOINT+0.420
- MTORC1_SIGNALING+0.370
- INTERFERON_GAMMA_RESPONSE+0.350
- GLYCOLYSIS+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.220
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- TGF_BETA_SIGNALING-0.470
- ANGIOGENESIS-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- UV_RESPONSE_DN-0.340
- NOTCH_SIGNALING-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- HEDGEHOG_SIGNALING-0.260
- APICAL_JUNCTION-0.230
- KRAS_SIGNALING_UP-0.230
- IL6_JAK_STAT3_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617854 | — | C | 0.895 |
| 2 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.868 |
| 3 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.858 |
| 4 | SRR8613729 | — | E | 0.850 |
| 5 | SRR8518323 | — | E | 0.849 |
| 6 | SRR8518144 | — | E | 0.842 |
| 7 | TCGA-A2-A0CW-01A-21R-A115-07 | — | B | 0.839 |
| 8 | SRR11296733 | — | — | 0.832 |
| 9 | TCGA-BH-A0EE-01A-11R-A034-07 | — | C | 0.829 |
| 10 | TCGA-A2-A4S3-01A-21R-A266-07 | — | B | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |